How do Fu Wei’s Restricted Share Units at NovaBridge Biosciences (NBP) vest?

The 1,010,100 Restricted Share Units vest over two years in equal annual installments. Specifically, they vest on June 29, 2027 and June 29, 2028, subject to continued service and any plan conditions, providing time-based alignment between Fu Wei’s compensation and the company’s performance.

What are the vesting conditions for Fu Wei’s 2025 Employee Share Options at NBP?

Each option tranche vests only if specific ADS price hurdles are met. They vest in eight equal quarterly installments after the 30-trading-day weighted average ADS price reaches $8.00, $12.00 and $16.00, respectively, linking Fu Wei’s potential option value to sustained share price performance.

How are NovaBridge Biosciences (NBP) ADSs related to Ordinary Shares in Fu Wei’s awards?

The filing states that each Restricted Share Unit represents a contingent right to receive one ADS. It also notes that each 10 ADSs represent 23 Ordinary Shares, clarifying the relationship between the listed ADSs and the company’s underlying Ordinary Shares referenced in the option grants.

Fu Wei at NovaBridge (NBP) awarded RSUs and long-dated options

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

NovaBridge Biosciences director Fu Wei received equity-based compensation awards. On June 29, 2026, Fu Wei was granted 1,010,100 Restricted Share Units, each representing a contingent right to receive one American Depositary Share (ADS). These RSUs vest in equal annual installments on June 29, 2027 and June 29, 2028.

On the same date, Fu Wei was also granted three tranches of 2025 Employee Share Options covering 1,087,720, 1,087,720 and 725,140 underlying Ordinary Shares at an exercise price of $2.45 per share, expiring on June 29, 2036. Each option tranche vests, if at all, in eight equal quarterly installments after the issuer’s ADS 30-trading-day weighted average price reaches $8.00, $12.00 and $16.00, respectively.

Insider Trade Summary

4 transactions reported

Mixed 4 txns

Insider Fu Wei

Role null

Type	Security	Shares	Price	Value
Grant/Award	2025 Employee Share Option (right to buy)	725,140	$0.00	--
Grant/Award	2025 Employee Share Option (right to buy)	1,087,720	$0.00	--
Grant/Award	2025 Employee Share Option (right to buy)	1,087,720	$0.00	--
Grant/Award	Restricted Share Units	1,010,100	$0.00	--

Holdings After Transaction: 2025 Employee Share Option (right to buy) — 725,140 shares (Direct, null); Restricted Share Units — 1,010,100 shares (Direct, null)

Footnotes (1)

Number of underlying securities and exercise price expressed in terms of American Depositary Shares ("ADS"). The option vests, if at all, in eight equal quarterly installments following the date on which the 30-trading-day weighted average price of the Issuer's ADS (based on trading days only) is at or above US$8.00. The Ordinary Shares may be represented by ADSs. Each 10 ADSs represent 23 Ordinary Shares of the Issuer. The option vests, if at all, in eight equal quarterly installments following the date on which the 30-trading-day weighted average price of the Issuer's ADS (based on trading days only) is at or above US$12.00. The option vests, if at all, in eight equal quarterly installments following the date on which the 30-trading-day weighted average price of the Issuer's ADS (based on trading days only) is at or above US$16.00. Each restricted stock unit ("RSU") represents a contingent right to receive one ADS. The RSUs vest over two years in equal annual installments on June 29, 2027 and June 29, 2028.

Key Figures

RSU grant size: 1,010,100 RSUs Option tranche 1: 1,087,720 options at $2.45 Option tranche 2: 1,087,720 options at $2.45 +3 more

6 metrics

RSU grant size 1,010,100 RSUs Restricted Share Units granted on June 29, 2026

Option tranche 1 1,087,720 options at $2.45 2025 Employee Share Option, expires June 29, 2036; $8.00 ADS hurdle

Option tranche 2 1,087,720 options at $2.45 2025 Employee Share Option, expires June 29, 2036; $12.00 ADS hurdle

Option tranche 3 725,140 options at $2.45 2025 Employee Share Option, expires June 29, 2036; $16.00 ADS hurdle

ADS to Ordinary ratio 10 ADSs = 23 Ordinary Shares Relationship between ADSs and Ordinary Shares

RSU vesting dates June 29, 2027 and June 29, 2028 Equal annual installments for RSUs

Key Terms

Restricted Share Units, American Depositary Shares ("ADS"), 2025 Employee Share Option, 30-trading-day weighted average price, +1 more

5 terms

American Depositary Shares ("ADS") financial

"Number of underlying securities and exercise price expressed in terms of American Depositary Shares ("ADS")."

American depositary shares are U.S.-listed certificates issued by a bank that represent ownership in shares of a foreign company, trading on American exchanges in dollars. Think of them as voucher tickets that let U.S. investors buy and sell foreign stock without handling foreign exchanges, currencies, or settlement rules directly. They matter because they make cross-border investing simpler and can affect liquidity, dividend payments and currency exposure for investors.

30-trading-day weighted average price financial

"The option vests, if at all, after the 30-trading-day weighted average price of the issuer's ADS reaches specified levels."

contingent right financial

"Each restricted stock unit ("RSU") represents a contingent right to receive one ADS."

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/30/2026 - 04:16 PM Accepted by SEC EDGAR 06/30/2026 - 04:15 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Fu Wei

(Last)

(First)

(Middle)

C/O NOVABRIDGE BIOSCIENCES

2440 RESEARCH BOULEVARD, SUITE 400

(Street)

ROCKVILLE

MARYLAND

20850

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
NovaBridge Biosciences [ NBP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
2025 Employee Share Option (right to buy)	$2.45⁽¹⁾	06/29/2026		A		725,140⁽¹⁾		⁽²⁾	06/29/2036	Ordinary Shares⁽³⁾	725,140⁽¹⁾	$0	725,140⁽¹⁾	D
2025 Employee Share Option (right to buy)	$2.45⁽¹⁾	06/29/2026		A		1,087,720⁽¹⁾		⁽⁴⁾	06/29/2036	Ordinary Shares⁽³⁾	1,087,720⁽¹⁾	$0	1,087,720⁽¹⁾	D
2025 Employee Share Option (right to buy)	$2.45⁽¹⁾	06/29/2026		A		1,087,720⁽¹⁾		⁽⁵⁾	06/29/2036	Ordinary Shares⁽³⁾	1,087,720⁽¹⁾	$0	1,087,720⁽¹⁾	D
Restricted Share Units	⁽⁶⁾	06/29/2026		A		1,010,100⁽¹⁾		⁽⁷⁾	⁽⁷⁾	Ordinary Shares⁽³⁾	1,010,100⁽¹⁾	$0	1,010,100⁽¹⁾	D

Explanation of Responses:

1. Number of underlying securities and exercise price expressed in terms of American Depositary Shares ("ADS").

2. The option vests, if at all, in eight equal quarterly installments following the date on which the 30-trading-day weighted average price of the Issuer's ADS (based on trading days only) is at or above US$8.00.

3. The Ordinary Shares may be represented by ADSs. Each 10 ADSs represent 23 Ordinary Shares of the Issuer.

4. The option vests, if at all, in eight equal quarterly installments following the date on which the 30-trading-day weighted average price of the Issuer's ADS (based on trading days only) is at or above US$12.00.

5. The option vests, if at all, in eight equal quarterly installments following the date on which the 30-trading-day weighted average price of the Issuer's ADS (based on trading days only) is at or above US$16.00.

6. Each restricted stock unit ("RSU") represents a contingent right to receive one ADS.

7. The RSUs vest over two years in equal annual installments on June 29, 2027 and June 29, 2028.

	/s/ Kyler Lei as attorney-in-fact	06/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What equity awards did Fu Wei receive from NovaBridge Biosciences (NBP)?

Fu Wei received significant equity-based compensation, including 1,010,100 Restricted Share Units and three tranches of 2025 Employee Share Options. The options cover 1,087,720, 1,087,720 and 725,140 underlying Ordinary Shares at a $2.45 exercise price, all granted on June 29, 2026.

What is the exercise price and expiration date of Fu Wei’s options at NovaBridge Biosciences (NBP)?

All 2025 Employee Share Options granted to Fu Wei have a $2.45 exercise price per underlying Ordinary Share. These options expire on June 29, 2036, giving a long-duration window during which vested portions can potentially be exercised, subject to the applicable plan rules.

Were Fu Wei’s NovaBridge Biosciences (NBP) transactions open-market buys or sales?

No, the reported transactions are equity awards, not open-market trades. All four entries use transaction code “A” for grants or awards, reflecting acquisitions of RSUs and options as compensation, with no indicated open-market buying or selling of existing NovaBridge shares or ADSs.